Hikma Pharmaceuticals: Company Profile, Product Portfolio
by Pharmchoices
Hikma Pharmaceuticals PLC is a pharmaceutical company that is engaged in the development, manufacture and marketing of injectables, branded generics, and oral and non-injectable generic and specialty products.
The company was started in Amman, Jordan in 1978, by Samih Darwazah. It started exporting to the US market in August 1996, becoming the first Arab pharmaceutical company to do so. It also acquired the West-Ward Pharmaceuticals in the 1990s.
In the 1980s, the company expanded into the MENA region, and had its first FDA-inspected manufacturing plant in the region
It acquired the Algerian company Al Dar Al Arabia Pharmaceutical Manufacturing Company for penicillin production in 2010. In the same year, it acquired Baxter’s U.S. injectable generics, with 41 products across 23 therapeutic areas. Baxter transferred the Cherry Hill manufacturing facility, the warehouse, and distribution centers to the group after the acquisition.
The group also acquired 63.9% of Société de Promotion Pharmaceutique du Maghreb S.A (Promopharm), a Moroccan pharmaceutical giant, for $111.2 million.
In 2014, Hikma acquired the US generic injectables, Bedford Laboratories, from Ben Venue Laboratories, a member of the Boehringer Ingelheim Group, in a deal worth US$300m.
Hikma acquired Roxane Laboratories Inc. (owned by Boehringer Ingelheim), a US specialty generics company, for US$1.18 billion. The manufacturing site in Columbus, Ohio produces solid, liquid, dry powder inhaler and nasal spray dosage forms.
In 2022, it is the third-largest pharmaceutical company in MENA, and the third-largest generic injectable company by volume in the US. The company also acquired the Custopharm, based in California for $425m, and also the Teligent’s Canadian assets for $45.75M. The acquisitions boosted the injectable portfolio and also marked the entry of Hikma into the Canadian market.
Other businesses by the company include the Arab Medical Containers (AMC), that produces plastic specialised medicinal sterile containers, and the International Pharmaceuticals Research Centre (IPRC), which conducts bio-equivalency studies. This resulted in more revenues.
Said Darwazah is the current Executive Chairman and Chief Executive Office of Hikma Pharmaceuticals.
Company Profile
Name: Hikma Pharmaceuticals PLC
Incorporated: 2005
Global Headquarters: 1 New Burlington Place, London, W1S 2HR, UK
Hikma has up to 760+ products under three main segments: Injectables and oral generics, branded generics and specialty products. There are also three R&D facilities.
The 32 manufacturing facilities which include 13 US FDA-inspected plants and 12 EMA-inspected plants are found in US, Middle East and North Africa (MENA), and Europe. They include:
Europe: Hikma also have manufacturing sites in European states Germany, Italy, and three in Portugal.
MENA: The MENA manufacturing locations include Jordan, Saudi Arabia, Algeria, Morocco, Tunisia, Sudan. There are R&D sites in Saudi Arabia, Jordan, Algeria, and Egypt.
Hikma in the US: Hikma has two large generic injectable, non-injectable and specialty products manufacturing sites in New Jersey and Ohio.
Products
In 2022, injectable generated about $1,141m, which is 45% of the revenue, while branded products generated $691m (27%), and generics, $672m (27%). Other products generated $13m. The top-selling markets include United States, Saudi Arabia, Egypt, and Algeria.
Hikma acquired US based pharma company Custopharm for $425m, and the Teligent’s Canadian assets, increasing their injectables portfolio and sales.
Product Line:
Active pharmaceutical ingredients: Oral and injectable oncology products, oral nasal sprays, corticosteroids.
Generics: Tablets, capsules, oral solutions, nasals. Top products include Butalbital-acetaminophen-caffiene’, Captopril, Colchicine, Doxycycline, Prednisone
